Place of Origin: | CHINA |
---|---|
Brand Name: | TINGYI |
Certification: | GMP , ISO 9001:2008 |
Model Number: | 83-43-2 |
Minimum Order Quantity: | Negotiation |
Price: | Contact Us |
Packaging Details: | Stealth And Discreet Packaging |
Delivery Time: | Within 7 Work Days |
Payment Terms: | Bank Transfer - Bitcoin - Western Union - MoneyGram |
Supply Ability: | 100 KG/Month |
Product Name: | Methylprednisolone | CAS: | 83-43-2 |
---|---|---|---|
Appearance: | White Powder | Shipping Method: | EMS, HKEMS, FEDEX, DHL, UPS, Aramex, ETC |
MF: | C22H30O5 | MW: | 374.47 |
High Light: | pharmaceutical active ingredients,pharmaceutical anabolic steroids |
White Powder Pharmaceutical Material Methylprednisolone Anti Estrogen Steroids For Rheumatoid Arthritis CAS 83-43-2
Methylprednisolone
CAS:83-43-2
MF:C22H30O5
MW:374.47
EINECS:201-476-4
Synonyms:(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione;11,17,21-trihydroxy-6-methyl-1,4-pregnadiene-3,20-dione ;11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione;11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione;1-dehydro-6alpha-methylhydrocortisone ;20-dione,11,17,21-trihydroxy-6-methyl-,(6alpha,11beta)-pregna-4-diene-3 ;20-dione,11-beta,17,21-trihydroxy-6-alpha-methyl-pregna-4-diene-3 ;20-dione,11beta,17,21-trihydroxy-6alpha-methyl-pregna-4-diene-3
Properties
Melting point:228-237°C (dec.)
alpha D20 +83° (dioxane)
refractive index 82 ° (C=1, Dioxane)
storage temp. 0-6°C
solubility chloroform/methanol (9:1): 50 mg/mL, clear, faintly yellow
Merck 6111
Application
1. Anti-inflammatory treatment: |
(rheumatic disease: as a short-term adjunct) (to help patients pass through acute or critical periods): Posttraumatic osteoarthritis; synovitis caused by osteoarthritis; rheumatoid arthritis, juvenile rheumatoid arthritis (individual patients may need low dose maintenance treatment); acute or subacute bursitis; ankle arthritis; acute nonspecific tendon sheath inflammation; acute gouty arthritis; psoriatic arthritis; ankylosing spondylitis. Collagen disorder (immune complex disease): critical illness or maintenance therapy for the following diseases: Systemic lupus erythematosus (lupus nephritis); acute rheumatic myocarditis; systemic dermatomyositis (PM); polyarteritis nodosa; Goodpasture syndrome (Good pasture 's Syndrome). Skin disease: pemphigus; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative dermatitis; bullous dermatitis herpetiformis; severe seborrheic dermatitis; severe psoriasis; mycosis fungoides; urticaria. Allergy status: used to control the following to conventional treatment to deal with the serious damage caused by function or allergic diseases; bronchial asthma; contact dermatitis; atopic dermatitis; serum sickness; seasonal or perennial allergic rhinitis; allergic reaction; urticarial transfusion reaction; edema of acute non infective throat (epinephrine is the drug of choice). - eye disease: severe acute and chronic ocular allergy and inflammation, such as herpes zoster; iritis, iridocyclitis; chorioretinitis; diffusion type real uveitis and choroiditis; optic neuritis; sympathetic ophthalmia. Gastrointestinal disease: a critical period for patients to survive the following diseases; ulcerative colitis (systemic therapy); localized enterocolitis (systemic therapy). Respiratory disease: pulmonary sarcoidosis; beryllium poisoning; Combined with appropriate anti tuberculosis chemotherapy for fulminant or diffuse tuberculosis; Other methods cannot control Loeffler's syndrome (Loffler s Syndrome); aspiration pneumonia. Edema: diuretic and urinary proteinuria for spontaneous or lupus nephrotic syndrome without uremia. |
2. Immunosuppressive therapy: | organ transplantation. |
3. The treatment of blood diseases and tumors: |
- blood diseases: acquired (autoimmune hemolytic anemia); adult idiopathic thrombocytopenic purpura (only intravenous injection, intramuscular injection of taboo); adult secondary thrombocytopenia; erythroblastopenia (anemia); congenital (red blood cell) aplastic anemia. Tumor: palliative care for the following diseases; adult leukemia and lymphoma; childhood acute leukemia |
4. Treatment shock: |
Adrenal cortical insufficiency induced by shock, or because of adrenal cortical insufficiency and the shock had no response to conventional therapy (hydrocortisone for commonly used drugs; if you do not want to have the mineralocorticoid activity, using methylprednisolone). Hemorrhagic, traumatic, and surgical shock without response to conventional therapy. Although there is no perfect (double-blind) clinical research, but animal experiment data show possible methylprednisolone to conventional therapy (e.g., rehydration) invalid effective shock. See also section of "infectious shock" in "precautions". |
5. Other: |
Nervous system: Brain edema caused by primary or metastatic tumor, and (or) surgery and radiotherapy; acute severe stage of multiple sclerosis; acute spinal cord injury. Treatment should begin within 8 hours after trauma. - combined with appropriate antituberculous therapy for tuberculous meningitis with subarachnoid obstruction or occlusion. - involving nerve or myocardial trichinelliasis. - prevention of nausea and vomiting caused by cancer chemotherapy. |
6. Endocrine disorders: |
Primary or secondary adrenal insufficiency; Acute adrenocortical insufficiency; (the above disease hydrocortisone or hydrocortisone as the drug of choice, if necessary, can be combined with synthetic glucocorticoid and mineralocorticoid.) Patients who are known to have or may have adrenal insufficiency are administered before surgery and with severe trauma or disease. Congenital adrenal hyperplasia; non suppurative thyroiditis; cancer induced hypercalcemia. |
Testosterone | CAS: 58-22-0 |
Testosterone enanthate | CAS: 315-37-7 |
Testosterone cypionate | CAS: CAS: 58-20-8 |
Testosterone propionate | CAS: 57-85-2 |
Testosterone phenylpropionate | CAS: 1255-49-8 |
Testosterone isocaproate | CAS: 15262-86-9 |
Testosterone decanoate | CAS: 5721-91-5 |
Testosterone undecanoate | CAS: 5949-44-0 |
Methyltestosterone (17-Alpha-Methyl-Testosterone) | CAS: 65-04-3 |
Turinabol (4-Chlorotestosterone Acetate ,Clostebol Acetate) | CAS: 855-19-6 |
oral turinabol (4-Chlorodehydromethyltestosterone) | CAS: 2446-23-3 |
Oxymetholone (Anadrol) | CAS: 434-07-1 |
Oxandrolone (Anavar) | CAS: 53-39-4 |
Stanozolol (Winstroll) | CAS: 10418-03-8 |
Stanolone | CAS: 521-18-6 |
Mestanolone | CAS:521-11-9 |
Methandrostenolone (Dianabol, methandienone) | CAS:72-63-9 |
Nandrolone | CAS:434-22-0 |
Nandrolone Decanoate | CAS:360-70-3 |
Nandrolone Cypionate | CAS:601-63-8 |
Nandrolone Phenypropionate | CAS:62-90-8 |
Normethisterone | CAS:514-61-4 |
Trenbolone | CAS:10161-33-8 |
Trenbolone Acetate | CAS:10161-34-9 |
Tibolone | CAS:5630-53-5 |
Trestolone | CAS:3764-87-2 |
Metribolone (Methyltrienolone) | CAS:965-93-5 |
Tamoxifen Citrate (Nolvadex) | CAS:54965-24-1 |
Clomiphene citrate | CAS:50-41-9 |
Sildenafil citrate () | CAS:171599-83-0 |
Tadalafil (Cialis) | CAS:171596-29-5 |
Vardenafil | CAS:224785-90-4 |
Boldenone | CAS:846-48-0 |
Boldenone Acetate | CAS:846-46-0 |
Boldenone Undecylenate | CAS:13103-34-9 |